Physician profile

Stewart A Sharp

Hematology & Oncology · Bismarck, ND

NPI 1235124934

$2,013.74

in general payments reported to CMS, 2019-2025

27 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $417.49 2019
Merck Sharp & Dohme LLC $255.21 2019
Genentech USA, INC. $203.43 2019
E.R. Squibb & Sons, L.L.C. $200.69 2019-2020
Astrazeneca Pharmaceuticals LP $171.82 2019-2020
Genzyme Corporation $98.08 2019
Lilly USA, LLC $71.11 2019
Gilead Sciences, INC. $62.05 2019-2020
Pfizer INC. $60.54 2019
Janssen Biotech, INC. $52.15 2019
Ipsen Biopharmaceuticals, INC $46.25 2019
Celgene Corporation $38.72 2019
Seagen INC. $36.78 2019-2020
Eisai INC. $35.77 2019
Emd Serono, INC. $30.12 2019
Show all 27 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $29.44 2019-2020
Alexion Pharmaceuticals, INC. $28.02 2019
Sandoz INC. $23.46 2020
Astellas Pharma US INC $20.28 2020
Clovis Oncology, INC. $19.89 2019-2020
Pharmacyclics LLC, An Abbvie Company $18.31 2019
Jazz Pharmaceuticals INC. $17.28 2020
Daiichi Sankyo INC. $16.48 2020
Takeda Pharmaceuticals U.S.A., INC. $16.19 2019
Exelixis INC. $15.93 2019
Glaxosmithkline, LLC. $15.73 2020
Incyte Corporation $12.52 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stewart A Sharp

$2,013.74

in general payments reported 2019-2025

Years
2019-2020
Top company
Amgen INC.

https://glasscript.com/doctor/146094/stewart-a-sharp

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.